行情

NAVB

NAVB

Navidea生物制药
AMEX

实时行情|Nasdaq Last Sale

1.570
+0.010
+0.64%
盘后: 1.600 +0.03 +1.91% 17:07 09/17 EDT
开盘
1.580
昨收
1.560
最高
1.600
最低
1.500
成交量
11.50万
成交额
--
52周最高
3.150
52周最低
1.460
市值
4,735.63万
市盈率(TTM)
-3.5869
分时
5日
1月
3月
1年
5年
简报-Navidea 报告董事会组成的变化
reuters.com · 19小时前
Navidea Biopharmaceuticals 宣布更改董事会组成
DUBLIN, Ohio, September 17, 2021--Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced that on September 14, 2...
Business Wire · 19小时前
Navidea Biopharmaceuticals 董事会主席退休,接替人选
MT Newswires · 23小时前
Navidea Biopharma (NAVB) 报告第二季度亏损,未达到收入预期
Navidea (NAVB) delivered earnings and revenue surprises of 0.00% and -56.50%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 08/11 21:15
简报-Navidia Biopharmaceuticals Q2 收入 $261,000
reuters.com · 08/11 20:49
Navidea Biopharm EPS 在线,未实现收入
Navidea Biopharm (NYSE:NAVB): Q2 GAAP EPS of -$0.09 in-line. Revenue of $0.26M (-3.7% Y/Y) misses by $0.34M. Press Release
Seekingalpha · 08/11 20:03
尽管收入下降,Navidea 生物制药公司 Q2 亏损也在缩小
MT Newswires · 08/11 16:23
生物技术的未来一周(8 月 8 日至 14 日):Jazz Pharma FDA 的决定、收益泛滥和 IPO 成为焦点
Biopharma stocks ended higher for the week ending Aug. 6, as the sector latched on to the optimism that was evident in the broader markets. Earnings continued to flow in, triggering stock-specific moves, while clinical readouts also moved stocks during the...
Benzinga · 08/08 14:03
更多
财务预测
实际值(美元)
预测值(美元)
利润表更多
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流(美元)
同比(%)
了解NAVB最新的财务预测,通过NAVB每股收益,每股净资产,每股现金流等数据分析Navidea生物制药近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测NAVB价格均价为6.50,最高价位8.00,最低价为5.00。
EPS
机构持股
总机构数: 32
机构持股: 74.28万
持股比例: 2.46%
总股本: 3,016.32万
类型机构数股数
增持
7
15.81万
建仓
5
3.67万
减持
8
2.59万
平仓
24
8.40万
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
+0.49%
制药与医学研究
-0.10%
高管信息
Non-Executive Chairman/Independent Director
S. Kathryn Rouan
Chief Executive Officer/Chief Financial Officer/Chief Operating Officer/IR Contact Officer
Jed Latkin
Other
Michael Rosol
Director
John Scott
Independent Director
Amit Bhalla
Independent Director
Claudine Bruck
Independent Director
Alexander Cappello
Independent Director
Malcolm Witter
暂无数据
  • 全部
  • 财务报告
  • 内部人交易
更多
NAVB 简况
Navidea Biopharmaceuticals, Inc. (Navidea) is a biopharmaceutical company. The Company is focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. The Company focuses on two drug product diagnostic substances, including Tc99m tilmanocept and other diagnostic applications of Manocept platform, and NAV4694, and therapeutic development programs, including therapeutic applications of Manocept platform. It also focuses on developing multiple precision-targeted products based on Manocept platform by identifying the sites and pathways of undetected disease and provide diagnostic services. Manocept platform serves as the molecular backbone of Tc99m tilmanocept, the product developed and commercialized by Navidea based on the platform.

微牛提供Navidea Biopharmaceuticals Inc(AMEX-NAVB)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的NAVB股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易NAVB股票基本功能。